After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

A trial by Novo Nordisk of its GLP-1 blockbuster Ozempic (semaglutide) on diabetes and kidney disease patients was successful enough that it was halted for efficacy five months ago at the interim ...

From supplements to injectables to belly-fat blasting beverages, there are plenty of products that claim to speed weight loss ...

Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...

Ozempic and Mounjaro are both very popular for weight loss at the minute, but there's one big difference between the two ...

Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock ...

Novo Nordisk (NVO 0.46%), a Danish pharmaceutical company, is the developer of Ozempic, which is often referred to as a weight-loss drug.But there is actually a nuance, albeit an important one, to ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Novo Nordisk anticipates that the next round of medications targeted for price setting negotiations with the federal government will include its wildly popular diabetes drug Ozempic.. During a ...

Benzinga reached out to Novo Nordisk’s media team but has not heard back. One study analyzed data from 424,152 diabetic patients, of which 106,454 were treated with Ozempic.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...